170.98
前日終値:
$167.55
開ける:
$167.55
24時間の取引高:
1.98M
Relative Volume:
1.47
時価総額:
$22.56B
収益:
$1.53B
当期純損益:
$-214.69M
株価収益率:
-97.15
EPS:
-1.76
ネットキャッシュフロー:
$-43.68M
1週間 パフォーマンス:
+2.53%
1か月 パフォーマンス:
+12.05%
6か月 パフォーマンス:
+10.17%
1年 パフォーマンス:
+58.33%
Natera Inc Stock (NTRA) Company Profile
NTRA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
NTRA
Natera Inc
|
170.98 | 22.56B | 1.53B | -214.69M | -43.68M | -1.76 |
![]()
TMO
Thermo Fisher Scientific Inc
|
392.56 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
194.44 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
519.85 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
115.52 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
154.61 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-03-13 | 開始されました | RBC Capital Mkts | Outperform |
2025-01-23 | 開始されました | Barclays | Overweight |
2024-06-03 | 再開されました | Jefferies | Buy |
2024-04-08 | 再開されました | Craig Hallum | Buy |
2024-02-20 | ダウングレード | Raymond James | Strong Buy → Outperform |
2023-12-29 | 繰り返されました | BTIG Research | Buy |
2023-12-14 | 開始されました | Guggenheim | Buy |
2023-12-13 | 開始されました | Wolfe Research | Outperform |
2023-11-13 | アップグレード | Raymond James | Outperform → Strong Buy |
2023-09-28 | 開始されました | Bernstein | Mkt Perform |
2023-07-05 | 再開されました | JP Morgan | Overweight |
2023-05-05 | 開始されました | UBS | Buy |
2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
2022-08-25 | 開始されました | Credit Suisse | Outperform |
2022-04-25 | 開始されました | Stephens | Overweight |
2022-03-08 | 開始されました | Goldman | Buy |
2022-01-06 | 再開されました | Piper Sandler | Overweight |
2021-10-15 | 再開されました | Cowen | Outperform |
2021-06-15 | 開始されました | Raymond James | Mkt Perform |
2021-05-25 | 開始されました | Wells Fargo | Overweight |
2021-01-28 | 開始されました | Truist | Buy |
2020-10-08 | 開始されました | BTIG Research | Buy |
2020-09-28 | 開始されました | Morgan Stanley | Overweight |
2020-09-17 | 開始されました | SVB Leerink | Outperform |
2020-06-10 | 再開されました | Piper Sandler | Overweight |
2020-05-07 | アップグレード | JP Morgan | Neutral → Overweight |
2018-10-05 | 開始されました | JP Morgan | Neutral |
2018-07-05 | 繰り返されました | Piper Jaffray | Overweight |
2017-08-07 | 繰り返されました | Morgan Stanley | Overweight |
2016-11-10 | 繰り返されました | The Benchmark Company | Buy |
2016-05-23 | 繰り返されました | The Benchmark Company | Buy |
2016-05-11 | 繰り返されました | The Benchmark Company | Buy |
2016-04-19 | 開始されました | The Benchmark Company | Buy |
2015-09-28 | アップグレード | Wedbush | Neutral → Outperform |
2015-08-14 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2015-08-04 | 開始されました | Robert W. Baird | Outperform |
2015-07-27 | 開始されました | Morgan Stanley | Equal-Weight |
2015-07-27 | 開始されました | Piper Jaffray | Overweight |
2015-07-27 | 開始されました | Wedbush | Neutral |
すべてを表示
Natera Inc (NTRA) 最新ニュース
Natera Approves Equity Plan Amendment at Annual Meeting - TipRanks
DNA Testing Market Size, Share, and Forecast 2025-2033: Key - openPR.com
Natera: Growth Likely To Moderate, Despite Signatera Test Medicare Coverage (NASDAQ:NTRA) - Seeking Alpha
Non-Invasive Cancer Testing Market Forecast | Major Players: Guardant Health, Exact Sciences, Qiagen, Natera Inc. - openPR.com
Where are the Opportunities in (NTRA) - news.stocktradersdaily.com
Here's How Much You Would Have Made Owning Natera Stock In The Last 10 Years - Benzinga
Insider Sell: Gail Marcus Sells 4,000 Shares of Natera Inc (NTRA) - GuruFocus
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase - Yahoo Finance
Transcript : Natera, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02 - MarketScreener
Prenatal Genetic Counselling Market 2025-2032: Top Trends & - openPR.com
Natera at Goldman Sachs Conference: Strategic Growth and Expansion - Investing.com Australia
Natera at Goldman Sachs Conference: Strategic Growth and Expansion By Investing.com - Investing.com India
Insider Sell: Steven Chapman Sells Shares of Natera Inc (NTRA) - GuruFocus
Colorectal Cancer Diagnostics Market Size To Boom with Top Key - openPR.com
Natera stock gains after Leerink Partners reiterates outperform rating By Investing.com - Investing.com South Africa
Natera's Signatera test to be covered under Medicare - MSN
Medicare expands coverage for Natera’s Signatera MRD test By Investing.com - Investing.com South Africa
Sector Update: Health Care - marketscreener.com
Natera Inc (NTRA) Trading 4.28% Higher on Jun 4 - GuruFocus
Natera (NTRA) Gains Medicare Coverage for Genome-Based Cancer Te - GuruFocus
Natera stock gains after Leerink Partners reiterates outperform rating - Investing.com
Natera's Signatera test to be covered under Medicare (NTRA:NASDAQ) - Seeking Alpha
Natera, Inc. Announces Medicare Coverage for Signatera Genome - marketscreener.com
Natera (NTRA) Secures Medicare Coverage for Signatera MRD Assay | NTRA Stock News - GuruFocus
Natera announces Medicare coverage for Signatera MRD assay - TipRanks
Medicare expands coverage for Natera’s Signatera MRD test - Investing.com Australia
Natera Announces Medicare Coverage for Signatera™ Genome | NTRA Stock News - GuruFocus
Natera Announces Medicare Coverage for Signatera ™ Genome - Business Wire
Natera Announces Medicare Coverage for Signatera™ Genome - New Castle News
Natera (NasdaqGS:NTRA) Showcases 94% Sensitivity In Pan-Cancer Signatera Genome Study - simplywall.st
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025 - GuruFocus
Natera Inc.: Is The Recent Growth in Signatera Volumes Here To Stay? - Smartkarma
Natera Inc (NTRA) Shares Up 3.07% on May 27 - GuruFocus
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
When the Price of (NTRA) Talks, People Listen - news.stocktradersdaily.com
Natera Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting | NTRA Stock News - GuruFocus
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting - Yahoo Finance
Natera raises 2025 revenue outlook to $1.94B-$2.02B with 26% growth target - MSN
Transcript : Natera, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 10 - marketscreener.com
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Stocks Showing Rising Market Leadership: Natera Earns 82 RS Rating - Investor's Business Daily
There's Reason For Concern Over Natera, Inc.'s (NASDAQ:NTRA) Price - simplywall.st
Natera (NASDAQ:NTRA) Rating Lowered to “Sell” at StockNews.com - Defense World
Natera (NASDAQ:NTRA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Natera: The Clues In Q1 Earnings (NASDAQ:NTRA) - Seeking Alpha
NTRA: Piper Sandler Raises Price Target for Natera | NTRA Stock News - GuruFocus
Natera Inc (NTRA) 財務データ
収益
当期純利益
現金流量
EPS
Natera Inc (NTRA) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Marcus Gail Boxer | Director |
Jun 10 '25 |
Sale |
164.44 |
4,000 |
657,761 |
5,704 |
大文字化:
|
ボリューム (24 時間):